Therapy of delta hepatitis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 10, 2015, Pages

  Yurdaydin, Cihan ^a   Idilman, Ramazan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; FOSCARNET SODIUM; HEPATITIS DELTA VIRUS ANTIBODY; IMMUNOGLOBULIN M; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA; ANTIVIRUS AGENT; INTERFERON; NEW DRUG; NUCLEOSIDE; NUCLEOTIDE;

ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DRUG BIOAVAILABILITY; FOLLOW UP; HEPATITIS DELTA VIRUS; HUMAN; MORTALITY; NEPHROTOXICITY; NONHUMAN; ACUTE DISEASE; COMBINATION DRUG THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); HEPATITIS D; HEPATITIS D, CHRONIC; LIVER CIRRHOSIS; VIROLOGY;

ACUTE DISEASE; ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HEPATITIS D; HEPATITIS D, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; NUCLEOSIDES; NUCLEOTIDES;

EID: 84943339506     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021543     Document Type: Article

References (138)

1. Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. 2014. Treatment of hepatitis D patients with pegylated interferon: A real world experience. Antiviral Ther 19: 463-468.
2. Actis GC, Maran E, Rosina F, Saracco G, Rocca G, Rizzetto M, Bonino F, Verme G. 1987. Natural killer response to exogenous interferon in delta hepatitis: Boost or depression definedwithin the first week of therapy. Digestion 37: 51-58.
3. Alexandrov A, Lempp FA, Allweiss L, Bogomolov P, Voronkova N, Schwab M, Haag M, Wedemeyer H, Dandi M, Urban S. 2014. A proof-of-concept phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex. Hepatology 60 (Abstr.): LB-20.
4. Arendt E, Jaroszewicz J, Rockstroh J,Meyer-OlsonD, Zacher BJ,Mederacke I,Manns MP,Wedemeyer H, Cornberg M, Wursthorn K. 2012. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. Viral Immunol 25: 442-447.
5. Arrigoni A, Ponzetto A, Actis GC, Bonino F. 1983. Levamisole and chronic delta hepatitis. Ann Intern Med 98: 1024.
6. Barrera A, Guerra B, Notvall L, Lanford RE, Lanford RE. 2005. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol 79: 9786-9798.
7. Blanchet M, Sureau C. 2007. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the Nterminal 75 amino acid residues. J Virol 81: 5841-5849.
8. Bordier BB,Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, Glenn JS. 2002. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 76: 10465-10472.
9. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K,Meuse L, Kay MA, Casey JL, et al. 2003. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 112: 407-414.
10. Boyd A, Lacombe K, Miailhes P, Gozlan J, Bonnard P,Molina JM, Lascoux-Combe C, Serfaty L, Gault E, Desvarieux M, et al. 2010. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 17: 65-76.
11. Buti M, Homs, Rodriguez-Frias F, Funalleras G, Jardí R, Sauleda S, Tabernero D, Schaper M, Esteban R. 2011. Clinical outcome of acute and chronic hepatitis delta over time: A long-term follow-up study. J Viral Hepat 18: 434-442.
12. Calle Serano B, Großhenning A, Homs M, Funalleras G, Jardí R, Sauleda S, Tabernero D, Schaper M, Esteban R. 2014. Development and evaluation of a baseline-eventanticipation score for hepatitis delta. J Viral Hepat 21: e154-e163.
13. Canbakan B, Şentürk H, Tabak F, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, et al. 2006. Efficacy of interferon α-2b and lamivudine combination treatment in comparison to interferon α-2b alone in chronic delta hepatitis: A randomized trial. J Gastroenterol Hepatol 21: 657-663.
14. Caredda F, Rossi E, d'ArminioMonforte A, Zampini L, Re T, Meroni B, Moroni M. 1985. Hepatitis B virus-associated coinfection and superinfection with delta agent: Indistinguishable disease with different outcome. J Infect Dis 151: 925-928.
15. Caredda F, Antinori S, Re T, Pastecchia C, Moroni M. 1987. Course and prognosis of acute HDV patients. Prog Clin Biol Res 364: 267-276.
16. Casey JL, Niro GA, Engle RE, Chu CK, Gerin JL,Hornbuckle WE, Tennant BC, Korba BE. 1996. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon Basin: The roles of genotype III and HBV genotype F. J Infect Dis 174: 920-926.
17. Casey J, Cote PJ, Toshkov IA, Chu CK, Gerin JL, Hornbuckle WE, Tennant BC, Korba BE. 2005. Clevudine inhibits hepatitis delta virus viremia: A pilot study of chronically infected woodchucks. Antimicrob Agents Chemother 49: 4396-4399.
18. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot- Peignoux M, Boyer N, Pham BN, Maylin S, Bedossa P, Dény P, et al. 2006. Efficacy of peginterferon α-2b in chronic hepatitis delta: Relevance of quantitative RTPCR for follow-up. Hepatology 44: 728-735.
19. Chang J, Nie X, Gudima S, Taylor J. 2006. Action of inhibitors on accumulation of processed hepatitis delta virus RNAs. J Virol 80: 3205-3214.
20. Choi SS, Rasshofer R, Roggendorf M. 1989. Inhibition of hepatitis delta virus RNA replication in primary woodchuck hepatocytes. Antiviral Res 12: 213-222.
21. Chudy M, Hanschmann K-M, Bozdayi AM, Kreß JC, Nübling M; WHO Expert Committee on Biological Standardization. 2013. Collaborative study to establish aWorld Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays. Geneva, Switzerland.
22. Ciancio A, Rizzetto M. 2014. Chronic hepatitis D at a standstill: Where do we go from here? Nat Rev Gastroenterol Hepatol 11: 68-71.
23. Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU. 2010. Pharmacodynamics of PEG-IFN-α-2a in HIV-HCV co-infected patients: Implications for treatment outcomes. J Hepatol 53: 460-467.
24. Di Bisceglie AM, Martin P, Lisker-Melman M, Kassianides C,Korenman J, BergasaNV, Baker B, Hoofnagle JH. 1990. Therapy of chronic delta hepatitis with interferon alfa 2b. J Hepatol 11: S151-154.
25. Di Marco V, Giacchino R, Timitilli A, Bortolotti F, Crivellaro C, Calzia R, Iannuzzi C, Prestileo T, Vajro P, Nebbia G; WHO Expert Committee on Biological Standardization. 1996. Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)- based assays. J Viral Hepat 3: 123-128.
26. EASL Clinical Practice Guidelines. 2011. Management of chronic hepatitis C virus infection. J Hepatol 55: 245- 264.
27. EASL Clinical Practice Guidelines. 2012. Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185.
28. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S. 2006. Characterization of a hepatitis B and hepatitis delta receptor binding site. Hepatology 43: 750-760.
29. Erhardt A, GerlichW, Starke C,Wend U, Donner A, Sagir A, Heintges T, Häussinger D. 2006. Treatment of chronic hepatitis delta with pegylated interferon-α2b. Liver Int 26: 805-810.
30. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, et al. 2006. Impact of severity on outcome of antiviral therapy for chronic hepatitis C: Lessons fromthe HALT-C trial. Hepatology 44: 1675-1684.
31. Farci P, Karayiannis P, Brook MG, Smedile A, Lai ME, Balestrieri A, Saldanha JA, Monjardino J, Gerin J, Thomas HC. 1989. Treatment of chronic hepatitis delta virus (HDV) infectionwith human lymphoblastoid α interferon. Quart J Med 73: 1045-1054.
32. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D, et al. 1994. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330: 88-94.
33. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, Serra G, Lai ME, Loy M, Caruso L, et al. 2004. Long-term benefit of interferon α therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis. Gastroenterology 126: 1740-1749.
34. Farhat BA,Marinos G, DanielsHM,Naumov N,Williams R. 1995. Evaluation of efficacy and safety of thymus humoral factor-γ 2 in the management of chronic hepatitis B. J Hepatol 23: 21-27.
35. Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, et al. 2015. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: A randomized trial-ANRS HB02 VAC-ADN. Gut 64: 139-147.
36. Fung J, Lai CL, Seto WK, Yuen MF. 2011. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66: 2715-2725.
37. Garripoli V, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, Bonino F, Rizzetto M, Verme G, Craxi A, et al. 1994. Ribavirin treatment for chronic hepatitis D: A pilot study. Liver 14: 154-157.
38. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. 1995. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon α-2B. Results of a randomized controlled trial. Liver 15: 45-52.
39. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
40. Gheorge L, Iacob S, Simionov I, Vadan R, Constantinescu I, Caruntu F, Sporea I, Grigorescu M. 2011. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: A multicenter Romanian trial. J Gastrointestinal Liver Dis 20: 377-382.
41. Glenn JS. 2005. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol 307: 133- 149.
42. Glenn JS, Watson JA, Havel CM, White JM. 1992. Identification of a prenylation site in delta virus large antigen. Science 256: 1331-1333.
43. Gosso C, Frasca D, Doria G. 1992. Effect of synthetic thymic humoral factor (THF-γ 2) on T cell activities on immunodeficient aging mice. Clin Exp Immunol 87: 346-335.
44. Govindarajan S, Chin KP, Redeker AG, Peters RL. 1984. Fulminant B viral hepatitis: Role of delta agent. Gastroenterology 86: 1417-1420.
45. Grabowski J,Wedemeyer H. 2010. Hepatitis delta: Immune pathogenesis and clinical challenges. Dig Dis 28: 133-138.
46. Grabowski J, Yurdaydin C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V,Manns MP, Cornberg M, Wedemeyer H, et al. 2011. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int 31: 1395-1405.
47. Greco-Stewart VS, Schissel E, Pelchat M. 2009. The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III. Virology 386: 12-15.
48. Grellier L,Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K,McMaster P, Beranek P, Kennedy F, Kibbler H, et al. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348: 1212-1215.
49. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. 1995. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213: 292-299.
50. Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, et al. 2014.Understanding early serum hepatitisDvirus and hepatitis B surface antigen kinetics during pegylated interferon- α therapy via mathematical modeling. Hepatology 60: 1902-1910.
51. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, Ilter T, Batur Y. 2005. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 10: 721-726.
52. Han Z, Nogusa S, Nicolas E, Balachandran S, Taylor J. 2011. Interferon impedes an early step of hepatitis delta virus infection. PloS ONE 6: e22415.
53. Heidrich B, Yurdaydin C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalçın K, et al. 2014. LateHDV RNA relapse after peginterferon α-based therapy of chronic hepatitis delta. Hepatology 60: 87-97.
54. Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, McBurney R, Schmid P, Albrecht J, Kleiner DE, et al. 2014. Long term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 40: 93-104.
55. Hughes SA, Wedemeyer H, Harrison PH. 2011. Hepatitis delta virus. Lancet 378: 73-85.
56. Ilan YM, Klein A, Taylor J, Tur-Kaspa R. 1992. Resistance of hepatitis delta virus replication to α interferon treatment in transfected human cells. J Infect Dis 166: 1164-1166
57. Kabaçam G, Yakut M, Seven G, Karatayli SC, Nassiri C, Bozkaya H, Bozdayi AM, Idilman R, Yurdaydin C. 2011. Delta hepatitis may require prolonged treatment with interferon. Hepatology 54: p1039A.
58. Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçın K, Bozdayi AM, et al. 2012a. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol 23: 560-568.
59. Kabaçam G, Önder FO, Yakut M, Seven G, Karatayli SC, Karatayli E, Savas B, Idilman R, Bozdayi AM, Yurdaydin C. 2012b. Entecavir treatment of chronic hepatitisD. Clin Infect Dis 55: 645-650.
60. Kabaçam G, Wedemeyer H, Savas B, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, et al. 2014. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. Liver Int 34: 107- 115.
61. Karaca C, Soer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, Evirgen S, Akyuz F, Demir K, Besisik F, et al. 2013. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Antiviral Ther 18: 561-566.
62. Karatayli SC, Ulger ZE, Ergul AA, Keskin O, Karatayli E, Albayrak R, Ozkan M, Idilman R, Yalçın K, Bozkaya H, et al. 2014. Tumour necrosis factor α, interleukin-10, interferon-γ and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta. J Viral Hepat 21: 297-304.
63. Katorza E, Pecht M, Apte RN, Benharroch D, Burstein Y, Trainin N, Rager-Zisman B. 1987. Restoration of immunological response by THF, a thymic hormone, in mice infected with murine cytomegalovirus (MCMV). Clin Exp Immunol 70: 268-275.
64. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, Bozaci M, Besisik F, Cakaloglu Y, Okten A. 2005. α-Interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 49: 1135-1138.
65. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, Seo TH, Lim SD, Lee CH. 2009. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 51: 787-791.
66. Koh C, Yurdaydin C, Cooper S, Cory D, Dhari H, Haynes- Williams V,Winters MA, Bys M, Choong I, Idilman R, et al. 2014. Prenylation Inhibitionwith lonafarnib decreases hepatitis D levels in humans. Hepatology 60: 1092A- 1093A.
67. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, Hoofnagle JH. 1999a. Lamivudine for chronic delta hepatitis. Hepatology 30: 546-549.
68. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. 1999b. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 117: 1229- 1233.
69. Le Gal F, Brichler S, Checkaraou MA, et al. 2010. Results of a French national quality control for hepatitis delta virus RNA quantification. In EASL Monothematic Conference on Delta Hepatitis, Abstract Book, 98 pp. Istanbul, Turkey.
70. Lok ASF, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50: 661-662.
71. Lu M,Menne S, Yang D, Xu Y, Roggendorf M. 2007. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: Preclinical studies in the woodchuck model. Expert Opin Investig Drugs 16: 787-801.
72. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, Markova A, Bremer B, Schlaphoff V, Cornberg M, et al. 2014. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis 208: 1362-1373.
73. Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, et al. 2012. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55: 685-694.
74. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. 1994. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-α 2a: Utility of polymerase chain reaction in monitoring antiviral response. Hepatology 19: 1331-1336.
75. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, Michel ML. 2004. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40: 874-882.
76. Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, et al. 2007. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antiviral Ther 12: 381-388.
77. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. 2011. Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAgnegative chronic hepatitis B. J Hepatol 55: 61-68.
78. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, et al. 2013. Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. J Hepatol 59: 949-956.
79. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, et al. 1998. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28: 585- 589.
80. Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann HL, Rosenau J, Bock CT, et al. 2012a. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 56: 115-122.
81. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalçın K, Gurel S, Zeuzem S, Zachou K, et al. 2012b. Anti-HDV immunoglobulinMtesting in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon-α2a treatment. Antiviral Ther 17: 305-312.
82. Michel ML, Tiollais P. 2010. Hepatitis B vaccines: Protective efficacy and therapeutic potential. Pathol Biol (Paris) 58: 288-295.
83. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282: 103-107.
84. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, et al. 2013. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146: 1070-1083.
85. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, Fontana R, Little N, Campbell F, Smedile A, et al. 2005a. Lamivudine therapy in chronic delta hepatitis: A multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 22: 227-232.
86. Niro GA, Rosina F, Rizzetto M. 2005b. Treatment of hepatitis D. J Viral Hepat 12: 2-9.
87. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, Stanzione M, David E, Brancaccio G, Fontana R, et al. 2006. Pegylated interferon α-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44: 713-720.
88. Ormeci N, Bölükbaş F, Erden E, Coban S, Ekiz F, Erdem H, Palabıyıkoğlu M, Beyler AR, Balık I, Bölükbaş C, et al. 2011. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology 58: 1648-1653.
89. Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, Lamy ME, Otte JB, De Hemptinne B, Geubel A, et al. 1991. Patterns of hepatitis delta-virus reinfection and disease in liver-transplantation. Gastroenterology 101: 1649-1655.
90. Patterson JL, Fernandez-Larsson R. 1990. Molecular mechanisms of action of ribavirin. Rev Infect Dis 12: 1139- 1146.
91. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH,Wells FV, Chu CK, Gerin JL, Tennant BC, et al. 2001. Antiviral activity of clevudine [1-FMAU, 1-(2- fluoro-5-methyl-β, 1-arabinofuranosyl) uracil] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks. Hepatology 33: 254-266.
92. Petersen J, Dandri M, MierW, Lütgehetmann M, Volz T, von Weizsäcker F, HaberkornU, Fischer L, Pollok JM, Erbes B, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26: 335-341.
93. Ponzetto A, Hoyer BH, Popper H, Engle R, Purcell RH, Gerin JL. 1987. Titration of the infectivity of hepatitis D virus in chimpanzees. J Infect Dis 155: 72-78.
94. Pugnale P, Pazienza V, Guilloux K, Negro F. 2009. Hepatitis delta virus inhibits α interferon signaling. Hepatology 49: 398-406.
95. Ribeiro RM, Germanidis G, Powers KA, Pellegrin B, Nikolaidis P, Perelson AS, Pawlotsky JM. 2010. Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 202: 1309-1318.
96. Rizzetto M. 2009. Hepatitis D: Thirty years after. J Hepatol 50: 1043-1050.
97. Rizzetto M, Smedile A. 2015. Pegylated therapy of chronic hepatitis D: In need of revision. Hepatology 61: 1109- 1111.
98. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, Verme G. 1977. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18: 997-1003
99. Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. 1980. Transmission of hepatitis B virus-associated delta antigen in chimpanzees. J Infect Dis 141: 590-602.
100. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Aricò S, Calzia R, Picciotto A, Colombo M, Popper H. 1983. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 98: 437-41.
101. Rosina F, Saracco G, Sansalvadore F. 1989. α-Interferon in the treatment of chronic delta hepatitis. Ital J Gastroenterol 21: 141-145.
102. Rosina F, Pintus C, Meschievitz C, Rizzetto M. 1991. A randomized controlled clinical trial of a 12 month course of recombinant human interferon-α in chronic hepatitis delta hepatitis: A multicenter Italian study. Hepatology 13: 1052-1056.
103. Rosina F, Conoscitore P, Smedile A,Mangia A, Borghesio E, Martinotti R, Andriulli A, Rizzetto M. 2002. Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-γ 2: A pilot study. Dig Liver Dis 34: 285-289.
104. Samuel D, Muller D, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. 1993. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842-1847.
105. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, Gigou M, Bismuth A, Mathieu D, Gentilini P, et al. 1995. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 21: 333-339.
106. Sánchez-Tapias JM, Mas A, Costa J, Bruguera M, Mayor A, Ballesta AM, Compernolle C, Rodés J. 1987. Recombinant α 2c-interferon therapy in fulminant viral hepatitis. J Hepatol 5: 205-210.
107. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, Quer J, Esteban R, Buti M. 2010. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 52: 658-664.
108. Scherr M, Eder M. 2007. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 6: 444-449.
109. Sepp-Lorenzino L, Abrams M, Carayannopoulos L, Koser M, Ludmerer S, Charusse JB, Freedman D, Jadhav V, Raheev JG, Hinkle G, et al. 2014. ALN-HBV, a GalNAcsiRNA enhanced stabilization chemistry RNAi therapeutic for the treatment of chronic hepatitis B virus infection. Hepatology 60 (Abstr): 1091A.
110. Sheldon J, Ramos B, Toro C, Ríos P, Martínez-Alarcón J, Bottecchia M, Romero M, Garcia-Samaniego J, Soriano V. 2008. Does treatment of hepatitis B virus infection reduce hepatitis delta virus replication in HIV-HBVHDV- coinfected patients? Antiviral Ther 13: 97-102.
111. Smedile A, Farci P,Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, et al. 1982. Influence of delta infection on severity of hepatitis B. Lancet ii: 945-947.
112. Taylor JM. 2006. Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol 307: 1-23.
113. Taylor JM. 2012. Virology of hepatitis D virus. Semin Liver Dis 32: 195-200.
114. Urban S, Bogomolov P, Voronkova N, Allweiss L, Dandri M, Schwab M, Lemp FA, Haag M, Wedemeyer H, Alexandrov A. 2014. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Hepatology 60 (Abstr): LB-20.
115. Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A. 2005. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol 79: 6570-6573.
116. Visco-Comandini U, Lapa D, Taibi C, Angeletti C. 2014. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. Dig Liver Dis 46: 348-352.
117. Wagstaff AJ, Bryson HM. 1994. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48: 199-226.
118. Wedemeyer H, Manns MP. 2010. Epidemiology, pathogenesis and management of delta hepatitis: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 7: 31-40.
119. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, et al. 2011. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364: 322-331.
120. Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, et al. 2014. Prolonged therapy of hepatitis delta for 96 weeks with pegylated interferon-α-2a plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: the HIDIT-2 study. J Hepatol 60 (Abstr): S2-S3.
121. Wöbse M, Yurdaydin C, Ernst S, Hardtke S, Heidrich B, Bremer B, Keskin O, Idilman R, Koch A, Manns MP, Wedemeyer H, Hardtke S, Heidrich B. 2014. Early ontreatment HDV RNA kinetics are not predictive for longterm response to a Peg-IFN therapy of hepatitis delta. Hepatology 60 (Abstr): 974A.
122. Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA. 2000. Lamivudinehigh dose interferon combination therapy for chronic hepatitis B patients co-infectedwith the hepatitisDvirus. J Viral Hepat 7: 428-434.
123. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, et al. 2014. Anti HDV IgM as a marker of disease activity in hepatitis delta. PLoS ONE 9: e101002.
124. Wursthorn K, Lütgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, et al. 2006. Peginterferon α 2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44: 675- 684.
125. Xu DZ,Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, et al. 2013. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings. J Hepatol 59: 450-456.
126. Yakut M, Seven G, Baran B, Kabaçam G, Bozkaya H, Karataylı E, Bozdayı M, Idılman R, Yurdaydın C. 2010. Clevudine treatment of chronic delta hepatitis. In EASL Monothematic Conference on Delta Hepatitis, Abstract Book, pp. 154. Istanbul, Turkey.
127. Yalçin K, Değertekin H, Yurdaydin C, Bozdayi M, Bozkaya H. 2003. The role of HBeAg seroconversion in acute exacerbation of liver diseasewith termination of hepatitis B and D virus infection in a chronic hepatitis D patient during α interferon therapy. Eur J Gastroenterol Hepatol 15: 819-823.
128. Yan H, Zhong G, Xu G, HeW, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, et al. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1: e00049.
129. Yilmaz E, Baran B, Soyer OM, Onel M, Onel D, Ormeci AC, Gokturk S, Evirgen S, Akyuz F, Demir K, et al. 2014. Effects of polymorphisms in interferon l 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection. Clin Gastroenterol Hepatol 12: 1753-1758.
130. YuenMF, Chan HLY, Given B,Hamilton J, Schuleup T, Lewis DL, Lai CL, Locarnini S, Lau JY, Gish RG. 2014. Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection. Hepatology 60: LB-21.
131. Yurdaydin C. 2012. Treatment of chronic delta hepatitis. Semin Liver Dis 32: 237-244.
132. Yurdaydin C, Bozkaya H, Gürel S, Tillmann HL, Aslan N, Okçu-Heper A, Erden E, Yalçin K, Iliman N, Uzunalimoglu O, et al. 2002. Famciclovir treatment of chronic delta hepatitis. J Hepatol 37: 266-271.
133. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalçin K, Değertekin H, Bozdayi AM, Uzunalimoğlu O. 2007. A pilot study of two years of interferon in patients with chronic delta hepatitis. J Viral Hepat 14: 812-816.
134. Yurdaydin C, Bozkaya H, Onder FO, Sentürk H, Karaaslan H, Akdoğan M, Cetinkaya H, Erden E, Erkan-Esin O, Yalçin K, et al. 2008. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine þ interferon vs. interferon. J Viral Hepat 15: 314-321.
135. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. 2010. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 17: 749-756.
136. Zachou K, Yurdaydin C, DrebberU, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, et al. 2010. Quantitative HBsAg and HDV RNA levels in chronic delta hepatitis. Liver Int 30: 430-437.
137. Zavaglia C, Bottelli R, Smedile A, Iamoni G, Mondazzi L, Airoldi A, Lanzani F, Idéo G. 1996. A pilot study of thymosin- α1 therapy for chronic hepatitis D. J Clin Gastroenterol 23: 162-163.
138. Zhang E, Lu M. 2015. Toll like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus infection. Mol Microbiol Immunol 204: 11-20.